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1. Introduction 
Erectile dysfunction (ED) is a widespread problem affecting many men across all age groups 
and it is more than a serious quality of life problem for sexually active men. Over 30 million 
men suffer from ED in the U.S. 1 and it is becoming a public health issue. The prevalence of 
ED is very high and is expected to raise considerably over the next 25 years, impacting more 
than 300 million men by 2025 2. ED is defined as the persistent inability to maintain or 
achieve a penile erection sufficient for satisfactory sexual performance. Its etiology is 
multifactorial. Various aspects affect the expression/degree of ED and risk factors include 
age, diabetes mellitus, neurologic diseases, smoking and cardiovascular diseases (CVD), 
among others 3. Although the disorder has been described for more than 1000 years, the 
molecular basis and mechanisms of ED have yet to be completely understood. In the last 4 
decades, elucidation of the macroscopic structures of the erectile system 4-5 ushered in a new 
era of therapeutic options for erectile disorders. Later, new insights into erectile 
neurotransmission, 6 essentially the nitric oxide (NO) pathway, 7  resulted in rational 
alternatives as a treatment 8. Nowadays, advances in gene discovery and intensive research 
regarding different mechanisms which could lead to ED have increased the working 
knowledge of the pathways involved in this condition. This chapter will describe the basic 
penile physiology and the emergent mechanisms associated to pathophisiology of 
vasculogenic ED. Penile anatomy and physiology will be summarized in order to review the 
new insights regarding pathways and critical modifications observed in ED condition.  
2. Penile anatomy  
The penis is composed of three bodies of erectile tissue running in paralel; the corpus 
spongiosum, encompassing the urethra and terminating in the glans penis; and the two 
corpora cavernosa (CC) which function as blood-filled capacitors providing structure to the 
erect organ 9. The penile CC are highly specialized vascular structures that are 
morphologically adapted to their function of becoming engorged during sexual arousal. The 
trabecular smooth muscle constitutes approximately 40-50% of tissue cross-sectional area, as 
assessed by histomorphometric analysis 10. There are three main arteries in the penis: 
cavernosal, dorsal, and bulbourethral. All three arise from a shared branch of the internal 
pudendal artery and provide an extensive anastomotic network 11. Nowadays, there is a 
tendency to perform in vitro experiments using the pudendal artery instead of cavernosal 
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tissue to investigate patophysiological aspects of ED since this artery is the major resistance 
to penile engogerment during sexual stimulation. Novel findings suggest that the pudendal 
artery contributes 70% of the total penile vascular resistence 12. The arterial blood supply in 
the CC is mainly fed from the deep penile cavernosal artery 9, which causes corporal 
enlargement  during erection, whereas the deep dorsal artery causes glans enlargement. 
Venous drainage is not similar to arterial supply; there exists only one deep dorsal vein that 
runs alongside the dorsal arteries and nerves in Buck’s fascia above the tunica albuginea, 
which is a multilayered structure where emissary veins pass. The human penile venous 
system is generally described as a single deep dorsal vein accompanied by a pair of dorsal 
arteries positioned between the tunica albuginea and Buck’s fascia for the venous drainage 
13. The corpus spongiosum is erectile tissue analogous to CC, but with a thinner tunica 
albuginea. The urethra lies within the spongiosum. The innervations of the penis is both 
autonomic (sympathetic and parasympathetic) and somatic (sensory and motor). From the 
neurons in the spinal cord and peripheral ganglia, the sympathetic and parasympathetic 
nerves merge to form the cavernous nerves, which enter in the CC and corpus spongiosum 
to affect the neurovascular events during tumescence and detumescence 14.  
 
Fig. 1. Penile anatomy. Adapted from Fazio and Brock , 2004.15     
3. Physiology of Penile Erection 
Penile erection (PE) involves central and peripheral pathways. Tumescence is initiated after 
central processing and integration of tactile, visual, olfactory and imaginative stimuli. Upon 
sexual stimulation, signals are generated to the peripheral tissues involved. Thus, final 
response is mediated by coordinated spinal activity in the autonomic pathways to the penis, 
and also in the somatic pathways to the perineal striated muscles. Both central and 
peripheral regulation of PE involves several neurotransmitters and systems, of which details 
are still not completely known. Spinally, there seems to be a network consisting of primary 
afferents from the genitals, spinal interneurons, sympathetic, parasympathetic and somatic 
nuclei, which is capable of integrating all information. Peripherally, the balance between 
substances that control the degree of contraction of the cavernosal smooth muscle 
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determines the functional state of the penis 16. The dynamic interplay of vasoconstrictors 
and vasodilators in the penis establish the erect or flaccid state.  
PE is determined by pressure changes in the cavernosal arterioles and sinuses. The 
vasculature of the erectile mechanism differs from most vascular beds as it is composed of 
arterioles and hallow blood-filled sinuses, both which are lined with smooth muscle and 
endothelial cells 14 as previously described. In the flaccid state, this tissue is tonically 
contracted, allowing only a small amount of arterial flow for nutritional purposes. The 
partial pressure of oxygen (PO2) in the blood is around 35mmHg 17. On the other hand, 
dilation of the penile arteries is the first event in the development of erection. Its 
consequence is the increase of blood flow and pressure into the lacunar space. Then, the 
expansion of sinusoids blocks the incoming blood. Also, venous outflow is reduced by 
compression of venular spaces between the tunica albuginea and peripheral sinusoids. This 
stretches the tunica to its capacity and decreases the venous outflow to a minimum, leading 
to an increase in intracavernosal pressure, which is maintained at approximately 100mmHg 
(2). Thus, erection includes sinusoidal relaxation, arterial dilation and venous compression (3).  
3.1 Mechanisms mediating erection and penile relaxation 
In general, mechanisms leading to normal erectile function imply inter-connections among 
neurons, striated perineal muscles and androgens which are responsible for maintaining 
sexual behavior in adults. Locally, the stage of penile erection requires relaxation of 
cavernosal smooth muscle. It is triggered by release of substances from parasympathetic and 
non-adrenergic non-cholinergic nerves (NANC), which in turn promotes vascular and 
cavernosal relaxation, leading to an increase in blood flow and intracavernosal pressure 
resulting in erection (Figure 1). Although several vasodilators have been implicated in this 
process, nitric oxide (NO) still is the main vasodilator involved 18-19. In the penis, stimulation 
of parasympathetic nerves inhibits noradrenalin release and evokes acetylcholine (Ach) 
release, which binding to muscarinic receptors in endothelial cells promoting eNOS 
activation and consequently NO production. Cholinergic nerves have been demonstrated 
within the human cavernous smooth muscle and surrounding penile arteries and 
ultrastructural examination has also identified terminals containing cholinergic vesicules in 
the same area 20. Two decades ago, it was suggested that NO released from NANC increases 
the production of 3’,5’-cyclic guanosine monophosphate (cGMP), which in turn relaxes the 
cavernosal smooth muscle 7, 21. Nowadays, it is well known that NO plays a critical role in 
erectile function. NO is formed from the precursor amino acid, L-arginine, by enzymatic 
action of NOS, which exists as three main isoforms: neuronal NOS (nNOS), inducible 
(iNOS), and endothelial NOS (eNOS). All three isoforms have been detected in the penis, 
although nNOS and eNOS are the main constitutively active NOS enzymes expressed in 
penile tissues 22, it is activated by calcium entry into the cell, binding to calmodulin 
associated with enzymes 23.  
There are two main intracellular mechanisms for relaxing the cavernosal smooth muscle: the 
guanylate cyclase (GS)/cGMP and adenylate cyclase/cAMP pathways (Figure 3). NO is 
associated with GS/cGMP signaling, called NO/cGMP pathway. Upon its release, NO 
diffuses locally into adjacent smooth muscle cells of the corpus cavernosum and binds to 
soluble guanylyl cyclase (GC), which catalyzes the conversion of guanosine trisphosphate 
(GTP) to cGMP. This cyclic nucleotide then activates protein kinase G, also known as  
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Fig. 2. Sequence of events required for penile erection. Upon sexual stimulation, substances 
such as Ach and NO are released from endothelial cells, parasympathetic and NANC 
neuronal endings evoking vascular relaxation and consequently increase in blood flow. 
Thus, there is an increase in intracavernosal pressure resulting in penile erection.  
cGMP-dependent protein kinase I (cGKI), which decreases cytosolic Ca2+ by various 
mechanisms. cGMP also blocks RhoA migration avoiding Rho-kinase pathway activation, 
which is a step very important to penile relaxation. The decay in cytosolic Ca2+ 
concentration induces relaxation of the vascular and cavernosal smooth muscle cells, 
leading to dilation of arterial vessels, increased blood flow into the corpora cavernosa, and 
penile erection (Figure 3). Contributing to penile relaxation, substances such as 
prostaglandin E1 (PGE1) can bind to G protein coupled receptors and activate the enzyme 
adenylate cyclase, which catalyzes the conversion of adenosine monophosphate (AMP) to 
cyclic AMP (cAMP). This cyclic nucleotide activates protein kinase A (PKA), which also 
decreases the intracellular Ca2+. PGE1, injected intracavernosally, alone or in combination, is 
today the second-line treatment for ED 24. These second messengers, cGMP and cAMP 
activate protein kinase (PKG and PKA respectively), which in turn phosphorylate certain 
proteins and ion channels, resulting in opening of the potassium channels and 
hyperpolarization, sequestration of intracellular Ca+2 by the endoplasmatic reticulum, and 
inhibition of voltage-dependent Ca+2 channels, blocking the Ca+2 influx 25. Both, cGMP and 
cAMP levels are modulated by phosphodiesterase (PDE) enzymes, which cleave these 
signaling molecules to 5’GMP and 5’AMP, respectively (Figure 3). Phosphodisterase-5 
(PDE-5) is a key enzyme in the NO/cGMP signal transduction pathway and functions to 
restrain smooth muscle cells relaxation and erectile process 18. Predominantly expressed in 
CC, PDE-5 catalyzes the hydrolysis cGMP to the inactive metabolite 5’GMP. Nowadays, the 
PDE5 inhibitors are the first-line treatment for ED 26. 
Another mechanism which has been demonstrated to be involved in maintenance of the 
erectile process is the phosphatidylinositol 3-kinase (PI3-kinase) pathway that activates the 
serine/threonine protein kinase Akt (also known as PKB). It causes direct phosphorylation 
of eNOS, reducing the enzyme's calcium requirement and causing increased production of 
NO. It has been suggested that rapid, brief activation of nNOS initiates the erectile process, 
whereas PI3-kinase/Akt-dependent phosphorylation and activation of eNOS by augmented 
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blood flow and endothelial shear stress lead to sustained NO production and maximal 
erection 27.  
 
Fig. 3. Regulation of cavernosal smooth muscle relaxation by NO released from the nitrergic 
nerve and sinusoidal endothelium. Central and/or local excitation evoke stimulation of the 
endothelial cells and nitrergic nerves in the penis, causing Ca+2 influxes which promote 
eNOS and nNOS activation, increasing NO production. NO binds to soluble guanylate 
cyclase (GC) inside cavernous muscle smooth catalyzing the conversion of GTP in cyclic 
GMP (cGMP). AMPc and high levels of cGMP result in vasodilatation of arteries and 
sinusoidal spaces of the corpus cavernosum, by decreasing intracellular calcium 
concentration, which is due to activation of PKA and PKG, leading consequently to erection. 
In addition, PKA and PKG cause inhibition of calcium channels and activation of potassium 
channels. Abbreviations: CaM, calmodulin; nNOS, neuronal nitric oxide synthase; eNOS, 
endothelial nitric oxide synthase; GTP, guanosine triphosphate; GMP, guanosine 
monophosphate; cGMP, cyclic GMP; PDE5, phosphodiesterase type 5; PKG, protein kinase 
G; PKA, protein kinase A. 
3.2 Flaccidity and detumescense 
Rich adrenergic enervation found in the penis, mainly surrounding the cavernosal arteries, 
and norepinephrine has been suggested as the chief neurotransmitter derived from the 
symphatetic nervous system to control flaccidity and detumescense 8, 28. Also, the penis is 
kept in the flaccid state due to endothelins. Penile smooth muscle cells not only respond to, 
but also synthesize, endotelin-1 (ET-1)29. Vasoconstriction in erectile tissue induced by ET-1 
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appears to be predominantly mediated by ETA receptor. In the penis, ET-1/ETA receptor-
mediated biological effects involve activation of the inositol trisphosphate (IP3)/calcium 
(Ca2+) and RhoA/Rho-kinase signaling pathways 30. However, both ETA and ETB receptors 
have been found in human CC smooth muscle membranes, and it cannot be excluded that 
both receptor subtypes are functional 28. The role of ETB receptors in the CC has not been 
clarified. This receptor activation is known to possibly induce a NO-mediated decrease in 
penile vascular tone 31.  
The intracellular mechanism in the absence of arousal stimuli, initiates with activation of G 
proteins following ligand binding to membrane receptors in order to keep cavernosal 
arterioles and sinuses constricted, maintaining the penis in the non-erect state. Subsequently 
to G protein activation, two signaling pathways are brought into play to cause smooth 
muscle contraction in the arterioles and cavernosum: the well characterized Ca+2 dependent 
pathway (phopholipase C) and the recently identified RhoA/Rho-kinase pathway know as 
Ca+2 sensitization. The Rho-kinase pathway is intrinsically involved with the process of 
smooth muscle contraction. The Ca2+ sensitivity of smooth muscle reflects the ratio of 
activities of MLCP to myosin light-chain kinase (MLCK), resulting in contraction or 
relaxation. Activation of G-protein coupled receptors by several agonists such as endothelin, 
angiotensin II, and noradrenalin, leads to the exchange of GDP for GTP on the small 
monomeric GTPase RhoA. This event actives RhoA and is catalyzed by the guanine 
nucleotide exchange factors, which causes dissociation of RhoA from its biding partner, 
Rho-guanine dissociation inhibitor. As a result, RhoA translocates from the cytosol to the 
membrane, allowing the downstream activation of several effectors such as Rho-kinase. 
Phophorylation of the regulatory subunit of MLC phophatase by Rho kinase causes 
inhibition phosphatase activity, which increases the contractile response at a constant 
intracellular calcium concentration 32. It is now widely accepted that MLCK and the 
RhoA/Rho-kinase pathway are two major cellular targets for regulating Ca2+ sensitivity of 
myosin light chain, and they generally operate in parallel. RhoA/Rho-kinase activity is a 
fundamental component to keep the penis in the non-erect state, and this pathway is 
upregulated in ED. Also, the essential balance between contraction and relaxation in the 
penis, which is maintained by the RhoA/Rho-kinase and NO/cyclicGMP pathways, is 
modified in this pathology 33-34. It has been demonstrated that Rho-kinase antagonism 
stimulated rat penile erection independently of NO suggesting that this principle could be a 
potential alternative for ED treatment 35-36. Many studies have suggested that NO inhibits 
RhoA/Rho-kinase activity 37-38. Increased of RhoA/Rho-kinase activity may lead to 
abnormal contractility of the CC and has been suggested to be involved not only in ED, but 
in several diseases which are risk factors for ED such as hypertension and diabetes 39.  
Another mechanism involved in penile vasoconstriction in absence of arousal stimuli, is the 
phospholipase C  (PLC) pathway. The stimulation of PLC occurs through the binding of 
vasoconstrictors agonists, such as norepinephrine (NE), angiotensin II (Ang II), endothelin-1 
(ET-1) and others, to their respective receptors. PLC hydrolyzes phosphatidylinositol 4,5-
biphosphate (PIP2) to release IP3 (inositol 1,4,5-trisphosphate) and DAG (1,2-diacylglycerol). 
IP3 binds to specific receptors (IP3R) on the endoplasmatic reticulum (ER) to stimulate the 
release of Ca+2 from the intracellular stores. DAG directly stimulates protein kinase C 
(PKC), which can regulate smooth muscle tone by controlling ion channels, allowing Ca+2 
influx. PKC also phosphorylates multiple substrates to facilitate contraction (figure 4).  
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Fig. 4. Regulation of cavernosal smooth muscle contraction leading to penile flaccidity. 
Pathways mediating the contraction of smooth muscle in CC, which is regulated by an 
increase in cytosolic Ca+2, are illustrated.  
4. Emergent mechanisms associated with ED 
Various aspects of neurotransmission, impulse propagation, and intracellular transduction 
of signals in penile smooth muscle remain to be elucidated. Nevertheless, the information 
about mechanisms involved in erection is quickly increasing and details regarding new 
pathways are constantly being added. The renin-angiotensin system (RAS), TNF-, MAP 
Kinases and arginase II are some of the new insights in this field.  
4.1 Renin-angiotensin system 
In the past decade, it has become apparent that the renin-angiotesin system (RAS) is 
involved in the regulation of ED. There is evidence that the local RAS exists within the CC 40 
and that several active peptides, particularly angiotensin II (Ang II), may be involved in the 
erectile mechanism. Ang II is the main effector of RAS that regulates important physiologic 
functions. The conventional idea of RAS as a systemic system has been extended recently. 
Many organs and tissues have components of RAS, working in a paracrine manner 41. Tissue 
RAS synthesizes Ang II locally and is modulated independently of systemic RAS. It has 
been demonstrated that Ang II activates the RhoA/Rho-kinase pathway via AT1 receptor, 
which is dominantly expressed in the smooth muscle and endothelial cells of the blood 
vessel wall, leading to the inhibition of myosin light chain phosphatase (MLCP) 42-43. 
Another significant function of AT1 is to activate nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase, increasing reactive oxygen species (ROS) production. ROS 
rapidly react with NO, reducing its bioavailability, and also stimulate RhoA/Rho-kinase 
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activity44-45. Additionally, both Ang II 46 and AT1 47 were detected in endothelial and smooth 
muscle cells from CC, and comparing the different stages of penile flaccidity, tumescence, 
rigidity, and detumescence, Ang II levels were significantly higher during detumescence 47. 
Human CC produces and secretes physiological amounts of Ang II, as much as 200-fold 
greater than that in plasma46. Furthermore, in vivo experiments demonstrated that injection 
of Ang II into the CC terminated spontaneous erections observed in anesthetized dogs46. 
Chronic infusion of exogenous Ang II for 4 weeks induced ED in Sprague-Dawley rats 48. It 
seems that RAS is crucial in ED 49.  
Reinforcing the association of RAS and ED, agiotensin-converting enzyme (ACE) has been 
found in the endothelial cells of dog CC 50, and ACE mRNA expression is up-regulated in a rat 
model of arteriogenic ED, although it is expressed at very low levels in the penis of control 
rat51. Results from human CC smooth muscle showed that Ang II and NO interact to modulate 
penile function, since an AT1 antagonist potentiated sodium nitroprusside (a NO donor) and 
electrical field stimulation mediated CC relaxation. Also, the authors suggested that Ang II 
response involves the production of superoxide and the development of oxidative stress 52. 
Taken together, evidence from many studies suggests that the main function of the RAS 
system is Ang II-mediated contraction, contributing to maintenance of the penis in a flaccid 
state. However, the RAS system consists of two major arms: a vasoconstrictor/proliferative 
arm in which the major mediator is Ang II acting on AT1 receptors, and a 
vasodilator/antiproliferative arm in which the main effector is Ang-(1-7) acting via G protein-
coupled recetors Mas 53. The Ang-(1-7)-Mas axis may play an important role in penile erection. 
This receptor has been observed in rat CC, and it has been demonstrated that Ang-(1-7) acts as 
a mediator of penile erection by activation of Mas and subsequent NO release. Additionally, in 
the absence of Mas erectile function was severely compromised 54.  
4.2 TNF-  
The emerging role for tumor necrosis factor-alpha (TNF-) in ED has been discussed. It is a 
pro-inflammatory cytokine originally defined by its antitumoral activity and is involved in 
many cardiovascular diseases (CVD), including heart-failure and atherosclerosis55-56. In 
these diseases, TNF- plasma levels are significantly increased and the vascular 
endothelium is the major target for the actions of TNF-. In vivo administration of this 
cytokine induces impairment of endothelium-dependent relaxation in a diversity of vascular 
beds and decreases the release of NO 57. Endothelium dysfunction is a key event in the 
pathophysiology of ED and, importantly, endothelium dysfunction is impaired in the 
presence of increased oxidative stress and inflammatory conditions55. A low-grade 
inflammatory process is associated with several CVD, and accordingly, cytokines levels, 
including TNF-, are increased in response to inflammation and contribute to the changes in 
vascular reactivity observed in these conditions58-59. TNF- has been described as an 
important contributor to many cardiovascular disorders55. Patients with ED present 
increased expression and elevated plasma levels of inflammatory markers and mediators 
among them TNF-60, which have been also observed in patients with hypertension. An 
emerging basic science and clinical data base provides a strong argument for endothelial 
and smooth muscle dysfunction as a central etiologic factor in systemic and peripheral 
vascular diseases, such as ED. It has been raising the idea of ED as an early sign of CVD 61. 
Once CDV appears right after ED and after the levels of TNF- start to increase 62-63, seems 
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that this cytokine may represent not only a common point between ED and CVD, but its 
increasing levels associated with ED may be a predictor of cardiovascular events64.  
TNF- has been associated with Rho-kinase signaling in endothelial cells. This cytokine not 
only induces inflammatory gene transcription, but also activation of RhoA and Rho-kinase65. 
In addition, TNF- leads to increased Ca+2 sensitivity via activation of the RhoA/ROCK 
pathway, a mechanism that may contribute not only to TNF--induced airway 
hyperresponsiveness and hyperreactivity 66-67. It was recently demonstrated that TNF- KO 
mice shown increased number of spontaneous erections, also these animals have enhanced 
nNOS expression in CC tissue68 , which suggests that TNF- down regulates nNOS 
expression in this tissue 68. In another work, the same authors showed that TNF--infused 
mice displays decreased NANC-dependent relaxation and increased symphathetic-
mediated concentrations in vivo, which would contribute to penile detumecesce to occur 69. 
Enhanced direct adrenergic responses were also observed in CC tissue from these animals, 
and it was suggested that downregulation of eNOS and nNOS may be the mechanism 
underlying the functional modifications in CC strips from TNF- infused mice 69. 
Endothelin-1 not only induces vasoconstriction, but it also stimulates the expression of 
adhesion molecules and activates transcriptional factors responsible for the coordinated 
increase in the expression of many cytokines and enzymes, which can in turn lead to the 
production of inflammatory mediators 70. Additionally, RAS system and Ang II, the main 
known mediator of RAS, induces vascular injury through many mechanisms, including 
vasoconstriction, oxidative stress and inflammation. Both peptides have been shown to 
increase TNF- levels and this pro-inflammatory cytokine also positively regulates release 
of these vasoactive peptides71-72. Finally, sexual performance has been negatively associated 
with circulating levels of endothelial inflammatory parameters 73. Further studies are 
necessary to better clarify the role of TNF- in ED and its mechanism in CC dysfunction. 
The positive point is that now we have access to target anti-TNF-a therapy.  
4.3 Arginase  
The involvement of arginase in ED has been evident in recent years. Arginase catalyses the 
conversion of L-arginine to ornithine plus urea. Arginase exists in two isoforms, the hepatic 
type, arginase I and the extrahepatic type, arginase II 74. Both isoforms are expressed in 
human CC tissue 75, but it seems that arginase II is the predominant isoform involved in ED 
mainly when this condition is associated with age and diabetes 76-77. In mammalian cells, L-
arginine is used as a substrate by both NOS and arginase. NO is derived from L-arginine by 
nitric oxide synthase (NOS) and both endothelial (eNOS) and neuronal (nNOS) isoforms of 
the CC serve as sources to generate essential levels of NO. NO production depends on NOS 
activity and NOS protein expression. On the other hand, NO production absolutely depends 
on the availability of L-arginine to NOS, since NOS shares L-arginine as a common substrate 
with arginase 78. Considering this, L-arginine catabolism via the arginase pathway can act as 
an endogenous negative control system to regulate overall NO production. ED mechanisms 
involve oxidative stress and vascular inflammation 79, both of which have been associated 
with enhanced arginase activity and expression in the vasculature 77. Recently, it has been 
demonstrated that diabetes-induced ED involves elevated arginase activity and expression 
80. Also, previous studies suggest that arginase activity in the CC is increased by 
hyperglycemia and aging 81.  
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Aging-associated ED involves abnormalities at multiple levels of the NO/cGMP signaling in 
the penis. These include reduced NANC nerve fibers in CC, decreased constitutive NOS 
activity, impaired endothelium-dependent smooth muscle relaxation and reduced NO 
bioavailability 82-83. It has been observed that dietary L-arginine supplementation as well as 
acute infusion of L-arginine results in improved NO release and increased endothelium-
dependent vasodilatation in the penis 84. The basis by which L-arginine supplementation can 
improve the endothelial function and NO release is questionable. Studies have been shown 
that eNOS expression is upregulated with advanced age in the penis and in peripheral 
vasculature. However, eNOS activity is reduced such that, for any given concentration of L-
arginine, vascular production of NO is reduced 85-86. Nowadays, we have evidence of a 
biological role of arginase in regulating erectile function in the aged penile vascular bed at 
both the molecular and functional level. It has been demonstrated that penile endothelial 
cells isolated from the aged mouse penis overexpressed arginase and, as a result, decreased 
eNOS activity and impaired vascular function. Moreover, inhibition of arginase via an 
adeno-associated virus (AVV) gene transfer of anti-arginase in this tissue increases penile 
eNOS activity and cGMP levels, thus restoring endothelial-derived NO vasodilatation and  
erectile function 79, speculating that an antisence for arginase may represent a novel 
molecular therapeutic target for the treatment of age-associated vasculogenic ED. Regarding  
diabetes- associated ED, reduced nitrergic and endothelial dependent smooth muscle 
relaxation, as well as arginase activation and diminished NO production are involved 87-88. 
In addition, it has been well documented that a major causative factor contributing to ED in 
diabetic patients is the reduction in the amount of NO synthesis in CC. Recently, it was 
demonstrated that arginase II deletion prevents diabetes-impairment in CC relaxation 80. 
Since a specific arginase inhitor is not available, in this study they used diabetic arginase II 
knockout mice. These animals did not exhibit increased arginase activity and expression, as 
well as decreased nNOS and phospho-eNOS (at Ser-1177 and Thr-495) levels. Arginase has 
been involved in sexual disorders not only in men, but also in women. Administration of 
arginase inhibitors in vitro and  in vivo enhances  engorgement in male and female genitalia 
89. There is no doubt that arginase is involved in ED. However, more complete 
understanding about the exact mechanism leading to disruption of erectile dynamic by 
arginase is necessary, as well as further research.  
4.4 MAP-Kinases 
Mitogen-activated protein kinases (MAPK) are a group of serine/threonine protein kinases 
which play an important role in cellular process, such as proliferation, stress response 
apoptosis and immune defense 90. The extracellular-signal-regulated kinase 1/2 (ERK1/2), 
p38 MAPK and the JUN N-terminal kinase (JNK) are the three most defined MAPK 
pathways 91. Not long ago, evidence of involvement of ERK1/2 and p38 MAPK in the ED 
began. It seems that these MAPKs are indirectly associated with NOS regulation, which 
affects NO avaibility. It has been observed that ERK plays a key role in eNOS regulation 92. 
In addition, phosphorylation of eNOS catalysed by ERK can lead to enzyme inhibition, and 
it was shown that in vivo phosphorylation of eNOS by ERK is associated with a reduction in 
enzyme activity. ERK inhibits eNOS by phosphorylating the enzyme in endothelial cells 92. 
ERK has been involved in various pathological conditions; one major mechanism involved 
in the regulation of inflammatory processes is the activation of ERK 93. Regarding cavernosal 
tissue, an inhibitory influence on activity of eNOS by ERK has been described in humans 94. 
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The first study showing a link between ERK1/2 and the CC was published in 2002 and the 
authors demonstrated that this kinase is present and active in human CC. Also, they found 
that the endothelial expression of ERK was more pronounced than muscular expression, 
and tissue from patients with ED showed a higher expression of the active ERK 94. ERK can 
be triggered by cellular stresses such as oxidative stress and hyperglycemia, which play an 
important role in the development of diabetic complications 95, a disease associated with ED. 
Recently, it was demonstrated that ERK inhibition decreases arginase activity and improves 
CC relaxation in streptozotocin (STZ)-induced diabetic mice (Nunes, 2011). Hyperglycemia 
in STZ-induced diabetic mice stimulates adipogenic induction of lipid accumulation and  
 
Fig. 5. Emergent pathways involved in ED. The influence of renin-angiotensin system (RAS), 
TNF-, ERK and P38 MAPK, and Arginase II in ED are illustrated. Tissue RAS synthesizes 
Ang II locally, which acts via two different receptors: AT-1, leading to activation of RHO-
kinase and consequently MLPC inhibition, contributing to penile flaccid, or Ang-1-7 Mass 
axis G-protein coupled receptor evoking NO release and facilitating CC relaxation. 
Additionally, Ang II can activates p38, which is involved in NOS regulation. TNF- 
promotes downregulation of eNOS and nNOS, contributing to ED. In addition, TNF- may 
lead to increased Ca+2 sensitivity, via activation of the RhoA/ROCK pathway, (???) in the 
penis. Since arginase and eNOS share L-arginine as a common substrate, increased arginase 
activity can limit NO availability, making the erectile function difficulty. ERK and p38 
MAPKs are indirectly associated with NOS regulation, which affects NO avaibility. 
Inhibitors for ERK and p38 in CC tissue resulted in decreased arginase activity, suggesting 
an association between these kinases and arginase. However, this mechanism in ED still 
needs be clarified.  
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involves ERK signaling pathway 96. Also,  neuropathy is a common complication of long-
term diabetes 97. Accordingly, the recent study showed that diabetes increased expression of 
activated ERK and arginase activity in CC and this effect was blocked by acute treatment 
with PD98059 (an ERK inhibitor). Also, the impaired cavernosal relaxation from STZ-
diabetic mice was attenuated by treatment with an ERK inhibitor, observed in nitrergic and 
endothelium-dependent relaxation responses. The authors suggested that ERK inhibition 
prevents the elevation of penile arginase activity and protects against ED caused by diabetes 
98. However, the mechanism involving ERK and arginase in ED is unclear and needs to be 
better understood.  
There are a few studies associating ERK and P38 MAPK with ED. RhoA/Rho-kinase has 
been indicated as an upstream regulator of MAPK family members such as p38 MAPK 99. 
Increased p38 MAPK in response to stress stimuli, including hyperglycemia, contributes to 
diabetic somatic neuropathy 100. The first study connecting ED and p38 demonstrated that 
inhibition of p38 MAPK corrects nitrergic neurovascular function in diabetic mice CC 101. It 
has been described that Ang II markedly activates p38 MAPK 102-103 and inhibition of p38 
MAPK attenuates organ damage and improves vascular function in cardiovascular diseases 
104-105. Recently, it was demonstrated that p38 MAPK increases arginase activity and 
contributes to endothelial dysfunction in CC 106. This study showed that acute treatment 
with p38 inhibitor prevents increased arginase activity and expression of phosphorylated 
p38 MAPK levels in CC from mice treated with Ang II. Also, decreased eNOS 
phosphorylation at Ser-1177 due to Ang II treatment, was prevented. 106. Although further 
research is needed to better clarify the exact role of these kinases in ED, new insights 
pointed to these pathways as a new therapeutic target worthy of consideration for clinical 
trials.  
5. Endothelial dysfunction in vasculogenic ED 
A number of both clinical and preclinical studies on hypercholesterolemia, hypertension, 
diabetes, and aging have demonstrated endothelial dysfunction to be a critical factor in the 
development of vasculogenic ED 107. Since the erectile function is a mechanism which 
requires a sensitive balance between the vasodilators and vasoconstrictors agents, any 
modification or impairment in endothelial function contributes to ED. Nowadays, because a 
systemic endothelial may functionally manifest itself early in the penile endothelium, the 
possibility arises that ED may be an early indicator of cardiovascular diseases 61, 108-110. In 
addition, since the penis is a rich vascularized organ, penile erection is, in large part, a 
vascular event. The endothelium, which is a layer of epithelial cells that lines structures of 
the cardiovascular system, is pivotal to the regulation of vasomotor tone. Impaired 
vasodilatation is closely linked with endothelial dysfunction, and endothelial cells are the 
primary source of NO, which is a crucial vasodilatory neurotransmitter involved in the 
regulation of vascular wall function, specifically in the penis 19. At the cellular level, 
endothelial dysfunction results in impaired release of NO. Oxidative stress, which is directly 
toxic to the endothelium and also interferes with NO signaling, is a strong factor responsible 
for the endothelial dysfunction in ED. In addition, free radical damage and impaired 
function, as well as NO availability, also results in increased adhesion and aggregation of 
platelets and neutrophils, and the release of vasoconstrictor substances 111-112. Since the penis 
is a vascular organ, it may be very sensitive to changes in oxidative stress and systemic 
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levels of NO for many reasons. The small diameter of the cavernosal arteries and the 
eminent amount of endothelium and smooth muscle (per gram of tissue compared to  
other organs) may make the penile vascular bed a sensitive indicator of systemic vascular 
disease 61.  
Oxidative stress has been implicated in endothelial damage or destruction of NO 113 as 
previously mentioned. It occurs when cells are exposed to excessive levels of reactive oxygen 
species (ROS) as a result of an imbalance between pro-oxidants and the protective mechanisms 
conferred by antioxidants 114. ROS is a superoxide (O2-) which interacts with NO reducing NO 
bioavailability and resulting peroxynitrite (ONOO-) formation. It has been demonstrated that 
the blockade of NOS increased basal superoxide production in penile arteries, suggesting that 
the release of ROS is modulated by its interaction with endogenous endothelial-derived NO, 
probably by producing peroxynitrite that reduces the bioavailability of both radicals 115. In 
addition, peroxynitrite and superoxide have been reported to increase the incidence of 
apoptosis in the endothelium of cavernosal smooth muscle, resulting in denudation of 
endothelium and further reduction of available NO 116. NOS, enzyme responsible for NO 
generation, uses l-arginine as a substrate and promotes its oxidation with NADPH and O2 
consumption to yield citrulline and NO. NADPH oxidase is a big source of superoxide radicals 
and many authors have reported that up regulation of this enzyme is associated with an 
increased risk of vascular diseases 117. Also, superoxide anions plays a role in natural aging 
process and the prevalence and severity of ED increase with age.  
Another mechanism associated endothelial damage and ED is the recently indentified 
advanced glycation end products (AGEs). It is believed that when AGEs are increased, NO 
cannot interact with GS, resulting in decreased CGMP levels and ultimately functional ED. 
Recently, it has been demonstrated that inhibitors of AGE formation can prevent formation 
of a range of complications in experimental diabetic animals, including ED 118-119. AGEs are 
elevated in diabetic human penile tissue and it has been localized to the collagen of the 
penile tunica and corpus cavernosum 120. Furthermore, AGEs and their receptors have been 
described to elevate the activity of endothelin-1, a vasoconstrictor, in rat corpus cavernosum 
121, and AGEs production is associated with increased superoxide anion. O-linked N-
acetylglucosamine (O-GlcNAc) is the major AGE product implicated in cavernosal 
dysfunction in diabetic patients. It has been reported a significant increase in the O-GlcNAc 
modification of eNOS and reduced phosphorylation of eNOS at baseline and following 
electrical stimulation in cavernosal tissue from diabetic rats compared with the controls 122. 
Finally, increased AGEs has been reported in penile tissue from aged man 123.  
Although the vascular endothelium is capable of self-repairing in general, any disruption in 
the penile endothelium balance may affect the dynamic of erectile function since the intact 
endothelium is critical to normal erection. Increase production of ROS has been associated 
with decreased normal erectile response, mainly because the reduction in NO avaibility, 
which is also observed due to endothelium damage 113. Consequently, ED can be the result 
of any number of structural or functional abnormalities in the penile vascular bed. 
Accordingly, ED may result from occlusion of the cavernosal arteries by atherosclerosis 
(structural vascular ED), impairment of endothelial dependent and/or independent smooth 
muscle relaxation (functional vascular ED), or a combination of these factors. Thus, it seems 
that endothelial dysfunction is sometimes a primary factor involved in ED even though 
reduced NO from NANC nerves has a significant contribution in ED.  
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6. Conclusion 
The molecular and clinical understanding of ED continues to gain ground at a particularly 
fast rate. Significant scientific advances during the last 2 decades have increased our 
knowledge regarding physiology and pathophysiology of penile erection. Different parts of 
the pathways involving ED have been studied intensely and the investigations of new 
components in this mechanism are emerging. The main target in the mechanism associated 
with ED is still NO, and the deep understanding of NO/cGMP signaling has supported, not 
only the molecular understanding of the tumescence, but also added significantly in the 
treatment of the ED, including the possibility of stem cell use and gene therapy. Also, the 
new components found to be involved in ED may be a potential target for development of 
novel drugs. However, the erectile mechanism is not completely elucidated and despite the 
efficacy of current therapies, current knowledge remains insufficient to address a growing 
patient population who do not respond to conventional treatment.  
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